Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytokine co-presentation on targeted lipid nanoparticles enhances in vivo T cell engineering.

Biomaterials·2026
Same author

IVUS-Guided IVC Stenting as a Solution for Tumor-Related Lower Extremity Edema.

Journal of vascular surgery. Venous and lymphatic disorders·2026
Same author

RAEM: random-access electron microscopy for revisitable 3D imaging.

bioRxiv : the preprint server for biology·2026
Same author

FALCON: Closed-Loop Multi-Objective Optimization of Lipid Nanoparticles for Cell-Selective mRNA Delivery.

bioRxiv : the preprint server for biology·2026
Same author

Topical Anesthetics for Corneal Abrasions: Investigating Emergency Department Readmission Rates and Associated Risks.

Eye & contact lens·2026
Same author

Stereotactic Percutaneous Thermal Ablation of Primary and Metastatic Liver Tumors: A Prospective Registry-Based Study.

Journal of vascular and interventional radiology : JVIR·2026

Related Experiment Video

Updated: Aug 4, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Locally Advanced Lung Cancer.

Sarah Oh1, George N Botros1, Milan Patel1

  • 1Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.

Hematology/Oncology Clinics of North America
|April 6, 2023
PubMed
Summary

Consolidation immunotherapy improves survival for unresectable lung cancer, but new treatments are needed for progression and personalization. Ongoing trials explore novel agents to overcome current therapeutic challenges and improve outcomes.

Keywords:
Chemoradiation therapyImmune checkpoint inhibitorImmunotherapyLocally advanced lung cancerNon–small cell lung cancerRadiotherapyUnresectable non–small cell lung cancer

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.2K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Related Experiment Videos

Last Updated: Aug 4, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.2K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Trials

Background:

  • Consolidation immunotherapy following chemoradiation enhances survival in unresectable, locally advanced lung cancer.
  • Disease progression and treatment personalization remain significant hurdles in managing this patient population.
  • Current therapeutic strategies face limitations, particularly for patients with PD-L1 negative tumors, driver mutations, or poor performance status.

Purpose of the Study:

  • To review historical data that has driven current research in unresectable, locally advanced lung cancer.
  • To summarize ongoing clinical trials investigating novel therapeutic approaches.
  • To address the challenges of disease progression and treatment personalization in this cancer type.

Main Methods:

  • Review of historical clinical data.
  • Analysis of ongoing clinical trial designs and preliminary efficacy data.
  • Identification of unmet needs in unresectable, locally advanced lung cancer treatment.

Main Results:

  • Consolidation immunotherapy has demonstrated improved five-year survival rates.
  • Concurrent immunotherapy with novel agents shows promise but carries risks of increased toxicity.
  • Innovative therapies are essential for patients with specific tumor characteristics or poor performance status.

Conclusions:

  • Despite advances, challenges in disease progression and treatment personalization persist for unresectable, locally advanced lung cancer.
  • New treatment strategies, including concurrent immunotherapy and novel agents, are under investigation.
  • Continued research and clinical trials are crucial to develop more effective and personalized therapies.